Difference between revisions of "van den Boogaard M, et al, JAMA (2018), cited as Ref 80 in DOI: 10.1186/s13054-020-02882-x (Q10711)"
Jump to navigation
Jump to search
(Created claim: Second Author string (P150): Slooter AJC, #quickstatements; #temporary_batch_1592745892439) |
(Created claim: Third Author string (P151): Bruggemann RJM, #quickstatements; #temporary_batch_1592746008102) |
||
| Property / Third Author string | |||
| + | Bruggemann RJM | ||
| Property / Third Author string: Bruggemann RJM / rank | |||
| + | Normal rank | ||
Revision as of 13:28, 21 June 2020
Cited in: "COVID-19: ICU delirium management during SARS-CoV-2 pandemic" Research article in Crit Care; 2020 04 28 ; 24 (1) 176
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
van den Boogaard M, et al, JAMA (2018), cited as Ref 80 in DOI: 10.1186/s13054-020-02882-x
|
Cited in: "COVID-19: ICU delirium management during SARS-CoV-2 pandemic" Research article in Crit Care; 2020 04 28 ; 24 (1) 176
|
Statements
Effect of haloperidol on survival among critically ill adults with a high risk of delirium: the REDUCE randomized clinical trial (English)
0 references
2018
0 references
van den Boogaard M
0 references
Slooter AJC
0 references
Bruggemann RJM
0 references
